Aryx Therapeutics I Stock Cash And Equivalents
ARYXDelisted Stock | USD 0.0005 0.00 0.00% |
Aryx Therapeutics I fundamentals help investors to digest information that contributes to Aryx Therapeutics' financial success or failures. It also enables traders to predict the movement of Aryx Pink Sheet. The fundamental analysis module provides a way to measure Aryx Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aryx Therapeutics pink sheet.
Aryx |
Aryx Therapeutics I Company Cash And Equivalents Analysis
Aryx Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Aryx Therapeutics Cash And Equivalents | 2.95 M |
Most of Aryx Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aryx Therapeutics I is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Aryx Therapeutics I has 2.95 M in Cash And Equivalents. This is 99.64% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.89% higher than that of the company.
Aryx Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.Aryx Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Aryx Fundamentals
Return On Asset | -0.75 | ||||
Current Valuation | 237.58 K | ||||
Shares Outstanding | 33.46 M | ||||
Shares Owned By Institutions | 0.14 % | ||||
Number Of Shares Shorted | 89.05 K | ||||
Price To Book | 37.83 X | ||||
EBITDA | (14.18 M) | ||||
Net Income | (33.17 M) | ||||
Cash And Equivalents | 2.95 M | ||||
Cash Per Share | 0.09 X | ||||
Debt To Equity | (5.11) % | ||||
Current Ratio | 0.47 X | ||||
Book Value Per Share | (0.23) X | ||||
Cash Flow From Operations | (34.97 M) | ||||
Short Ratio | 0.79 X | ||||
Earnings Per Share | (0.59) X | ||||
Target Price | 1.5 | ||||
Number Of Employees | 56 | ||||
Beta | 0.0896 | ||||
Market Capitalization | 237.58 K | ||||
Total Asset | 12.41 M | ||||
Retained Earnings | (187.11 M) | ||||
Working Capital | 126 K | ||||
Current Asset | 8.62 M | ||||
Current Liabilities | 8.49 M | ||||
Z Score | -24.3 | ||||
Net Asset | 12.41 M |
About Aryx Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aryx Therapeutics I's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics I based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |